# Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation

> **NCT00838071** · PHASE3 · COMPLETED · sponsor: **Instituto Grifols, S.A.** · enrollment: 20 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Specific intravenous anti-hepatitis B immunoglobulin

## Key facts

- **NCT ID:** NCT00838071
- **Lead sponsor:** Instituto Grifols, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2004-07
- **Final completion:** 2004-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2009-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00838071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00838071, "Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00838071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*